Research Analysts Set Expectations for BMY Q2 Earnings

Bristol-Myers Squibb (NYSE:BMY) – Equities research analysts at William Blair issued their Q2 2026 earnings per share estimates for shares of Bristol-Myers Squibb in a research report issued on Friday, February 7th. William Blair analyst M. Phipps anticipates that the biopharmaceutical company will earn $1.59 per share for the quarter. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $6.75 per share. William Blair also issued estimates for Bristol-Myers Squibb’s Q3 2026 earnings at $1.65 EPS.

Several other research analysts have also recently issued reports on the company. Leerink Partners upgraded Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th. Morgan Stanley raised their price objective on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a research note on Tuesday, November 12th. Truist Financial upped their target price on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Wells Fargo & Company lifted their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Friday, February 7th. Finally, Wolfe Research started coverage on Bristol-Myers Squibb in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Trading Up 0.8 %

NYSE:BMY opened at $55.99 on Monday. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The stock’s 50 day simple moving average is $57.48 and its 200-day simple moving average is $53.97. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.10. The firm has a market cap of $113.56 billion, a P/E ratio of -12.67, a PEG ratio of 2.13 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.81%.

Institutional Investors Weigh In On Bristol-Myers Squibb

Several institutional investors and hedge funds have recently modified their holdings of BMY. Reston Wealth Management LLC acquired a new position in Bristol-Myers Squibb in the 3rd quarter worth $25,000. Hollencrest Capital Management increased its position in shares of Bristol-Myers Squibb by 61.3% during the third quarter. Hollencrest Capital Management now owns 492 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 187 shares during the last quarter. Kennebec Savings Bank acquired a new position in shares of Bristol-Myers Squibb in the third quarter worth about $28,000. Fairway Wealth LLC purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at about $28,000. Finally, Darwin Wealth Management LLC acquired a new stake in Bristol-Myers Squibb during the 3rd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were issued a dividend of $0.62 per share. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend was Friday, January 3rd. This represents a $2.48 annualized dividend and a dividend yield of 4.43%. Bristol-Myers Squibb’s payout ratio is presently -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.